

Exploring and expanding the CRISPR-Cas enzyme toolbox for genome editing

Jennifer Doudna / UC Berkeley / HHMI





Company connections

Co-founder:

Caribou Biosciences
Editas Medicine
Intellia Therapeutics
Mammoth Biosciences

SAB member:


Caribou Biosciences
Intellia Therapeutics
eFFECTOR Therapeutics
Mammoth Biosciences
Synthego

Inari


Director:

Johnson & Johnson

Biology → applications



biochemistry →



Research

Healthcare

Agriculture

Diagnostics

Synthetic biology

Therapeutics



Cas9 as an *in vivo* therapeutic: considerations

- Multiple clinical trials for somatic therapies will begin in 2019-20
- The most widely used enzymes for genome editing come from pathogenic bacteria
- Cas9 and Cas12a/Cpf1 are large proteins, complicating delivery
- Avoiding genome damage due to sustained activity is desirable



*MINING NATURAL DIVERSITY OF CRISPR SYSTEMS
TO ENHANCE IN VIVO APPLICATIONS*



New small CRISPR-Cas enzymes from non-pathogenic bacteria


CasX is part of a new kind of CRISPR locus

?



Adaptation/DNA integration



CasX-mediated transcriptional control in bacteria




CasX-mediated gene knockout in human cells



CasX makes 10-bp staggered dsDNA cut




CasX: smaller protein, larger sgRNA



1368aa

83nt

SpyCas9



986aa


122nt

CasX




Systematic discovery and validation of CRISPR-Cas inhibitors

Most CRISPR-Cas systems have natural inhibitors



A multiple-turnover inhibitor of Cas12a



Gavin Knott, Brittney Thornton, Kyle Watters
Watters et al. (2017) *Science*



Conclusions

- New CRISPR-Cas enzymes: alternative tools for *in vivo* genome editing and control
- Multiple-turnover CRISPR inhibitor could prevent genome damage

Acknowledgements



Jill Banfield – UC Berkeley
Eva Nogales – UC Berkeley
David Savage – UC Berkeley
David Burstein – University of Tel Aviv

Junjie Liu, Natalia Orlova, Lucas Harrington,
Janice Chen, Alex Wagner, Ben Oakes,
Christof Fellmann, Gavin Knott, Kyle Watters
Brittney Thornton



THE
PAUL G. ALLEN
FRONTIERS GROUP


U.S. Department of Health & Human Services




National Institutes
of Health



CasX: smaller protein, larger sgRNA



SpyCas9



CasX

